Liquid and Tissue Biopsy in the Treatment of NSCLC: Focus on MET Gene Aberrations

Liquid and Tissue Biopsy in the Treatment of NSCLC: Focus on MET Gene Aberrations

Liquid and Tissue Biopsy in the Treatment of NSCLC: Focus on MET Gene Aberrations

Learn about innovations in the development of liquid biopsy and how to use it to better identify treatment strategies for patients with NSCLC.

Available credits: 0.25

Time to complete: 15 minutes


Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    Lung cancer remains the most common cancer in the United States and Europe and second most common in Japan. Of patients with non-small cell lung cancer (NSCLC), approximately 3% to 4% have tumors that harbor MET gene aberrations including MET exon 14 skipping mutations. These patients have an even worse prognosis than others with NSCLC, and early diagnosis and targeted therapies are essential. Join us as Dr. Paul Paik and Dr. Jyoti Patel discuss the value that liquid biopsy brings to patients with NSCLC, specifically those with MET exon 14 skipping mutations.    

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. GLC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Paul K. Paik, MD
    Clinical Director, Thoracic Oncology
    Memorial Sloan Kettering Cancer Center
    New York, NY

    No relevant financial relationships 

    Jyoti D. Patel, MD, FASCO
    Professor of Medicine
    Northwestern University
    Robert H. Lurie Comprehensive Cancer Center
    Chicago, IL

    No relevant financial relationships 

    Reviewers/Content Planners/Authors:

    • Jorge Bacigalupo has nothing to disclose.
    • Ann Early has nothing to disclose.
    • Barry A. Fiedel, PhD, has nothing to disclose.
    • Tricia O’Leary has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Discuss the emerging role of liquid biopsy for initial tumor assessment and/or for treatment stratification among patients with NSCLC
    • Describe clinical data that provides proof of concept for the use of liquid biopsy when undertaking genomic testing in the management of NSCLC
  • Target Audience

    This activity is designed to meet the educational needs of medical oncologists.

  • Accreditation and Credit Designation Statements

    Global Learning Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Global Learning Collaborative designates this enduring material for a maximum of .25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    The American Medical Association has an agreement of mutual recognition of Continuing Medical Education (CME) credits with the European Union of Medical Specialists (UEMS), the accreditation body for European countries. Physicians interested in converting AMA PRA Category 1 CreditsTM to UEMS-European Accreditation Council for Continuing Medical Education CME credits (ECMECs) should contact the UEMS at

  • Provider

    ReachMD Healthcare Image

    AGILE - Academy for Interprofessional Learning and Education - designs, develops, and delivers education across a broad spectrum of diseases and clinical conditions.  Our mission is to serve as a trusted source of clinical information that helps healthcare professionals improve competence, performance, and patient outcomes

  • Commercial Support

    This activity is supported by an independent educational grant from the Healthcare business of Merck KGaA, Darmstadt, Germany.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and AGILE. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of AGILE you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited

    Reproduction of this material is not permitted without written permission from the copyright owner.

    Disclaimer: Some products discussed in this activity may not have received regulatory approval by the US FDA for the treatment of patients. The FDA has stated that “good medical practice and the best interests of the patient require that physicians use legally available drugs, biologics and devices according to their best knowledge and judgement”. 

Facebook Comments



We’re glad to see you’re enjoying Global Oncology Academy…
but how about a more personalized experience?

Register for free